Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

#### 144: Filer Information

Filer CIK 0001801061
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

#### 144: Issuer Information

Name of Issuer Arcutis Biotherapeutics, Inc.

SEC File Number 001-39186

3027 TOWNSGATE ROAD

SUITE 300

Address of Issuer WESTLAKE VILLAGE

CALIFORNIA

91361

Phone 805-418-5006

Name of Person for Whose Account the Securities are To Be Sold Watanabe Todd Franklin

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Securities
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	15000	227567.00	117044591	12/20/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

### 144: Securities To Be Sold

Title of the Name of Person from Is Date you Nature of Date Amount of Date of Nature of Class **Acquired** Acquisition Whom Acquired this Donor **Securities Payment** Payment \*

	Transaction	a Acquire Gift?	d Acquired	
Common	03/03/2023 Restricted Stock Vesting	ARCUTIS BIOTHERAPEUTICS  INC	2870	03/03/2023 NA
Common	03/03/2024 Restricted Stock Vesting	ARCUTIS BIOTHERAPEUTICS  INC	470	03/03/2024 NA
Common	03/01/2024 Restricted Stock Vesting	ARCUTIS BIOTHERAPEUTICS  INC	3080	03/01/2024 NA
Common	03/01/2023 Restricted Stock Vesting	ARCUTIS BIOTHERAPEUTICS  INC	4046	03/01/2023 NA
Common	02/27/2023 Restricted Stock Vesting	ARCUTIS BIOTHERAPEUTICS □ INC	4534	02/27/2023 NA

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Securities Sold	<b>Gross Proceeds</b>
Todd Watanabe 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361	Common	11/04/2024	13871	120039.00

# 144: Remarks and Signature

Remarks
Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

12/20/2024

06/14/2024

Amount of

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Todd Watanabe

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)